Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonrotoclax + Zanubrutinib vs Zanubrutinib in Untreated CLL
2024-513970-23-00Phase 2Authorised
- Sponsor
- BeOne Medicines
- Start
- Feb 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 2, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Sonrotoclax + Zanubrutinib with Zanubrutinib monotherapy (2 arms). Primary endpoint: Best CR/CRi rate per IRC. Planned start Feb 2025; status: authorised.
02
Drugs
sonrotoclaxzanubrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2024-513970-23-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513970-23-00.